Merck, Inc.
🇵🇭Philippines
Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Phase 1
Completed
- Conditions
- HIV InfectionsHIV
- Interventions
- Biological: V526
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 147
- Registration Number
- NCT00850616
A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: V512
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 187
- Registration Number
- NCT00851266
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Phase 1
Completed
- Conditions
- HIV-1HIV Infections
- Interventions
- Biological: V520
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT00849732
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Phase 1
Completed
- Conditions
- HIV-1HIV Infections
- Interventions
- Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 317
- Registration Number
- NCT00849680
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Phase 1
Completed
- Conditions
- Locally Advanced, Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00848718
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: MK5757
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 54
- Registration Number
- NCT00848484
Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)
Phase 3
Terminated
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 308
- Registration Number
- NCT00846781
A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)
Phase 2
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: MK1903
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 191
- Registration Number
- NCT00847197
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
Phase 2
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: MK8245 5 mg (twice a day) b.i.d.Drug: MK8245 50 mg b.i.d.Drug: Placebo
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT00846391
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 202
- Registration Number
- NCT00845065
© Copyright 2025. All Rights Reserved by MedPath